EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of acute exacerbation of chronic liver disease due to HBV by lamivudine



Treatment of acute exacerbation of chronic liver disease due to HBV by lamivudine



Hepatology 34(4 Pt 2): 656A, October




(PDF 0-2 workdays service: $29.90)

Accession: 035980755

Download citation: RISBibTeXText



Related references

Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long-term lamivudine therapy for hepatitis B e antigen-positive chronic hepatitis B. Journal of Medical Virology 73(1): 7-12, 2004

Lamivudine therapy in the treatment of chronic hepatitis B with acute exacerbation during pregnancy. Journal of the Chinese Medical Association 71(3): 155-158, 2008

Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Alimentary Pharmacology & Therapeutics 15(11): 1737-1744, November, 2001

Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment. Journal of Gastroenterology and Hepatology 23(8 Pt 1): 1242-1249, 2008

Lamivudine treatment for acute exacerbation of hepatitis B in patients undergoing immunesuppressive therapy Sequence analysis of precore/core region during lamivudine administration. Hepatology 32(4 Pt 2): 590A, October, 2000

Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antiviral Therapy 11(4): 465-471, 2006

Comparison of clinical outcome between patients continuing and discontinuing lamivudine therapy in acute exacerbation after viral breakthrough during lamivudine therapy in chronic hepatitis B. Korean Journal of Hepatology 12(2): 184-190, 2006

Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B. Antiviral Therapy 13(4): 571-579, 2008

Efficacy of lamivudine or entecavir on acute exacerbation of chronic hepatitis B. International Journal of Medical Sciences 9(1): 27-32, 2012

Lamivudine monotherapy for chronic hepatitis B infection with acute exacerbation revisited. European Journal of Gastroenterology & Hepatology 21(4): 447-451, 2010

Adequacy of immediate Lamivudine trial for chronic hepatitis B patients with acute exacerbation. Korean Journal of Hepatology 10(1): 22-30, 2004

Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B. Journal of Gastroenterology and Hepatology 20(3): 426-432, 2005

Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 32(3): 635-639, 2000

Rhabdomyolytic syndrome during the lamivudine therapy for acute exacerbation of chronic type B hepatitis. Liver Transplantation 8(12): 1198-1199, 2002